Sign inJoin waitlistJoin the waitlist

Georgios Pongas

Assistant Professor of Clinical Medicine · University of Miami/Jackson Health System

Credentials: · · · · · · · ·

History

University of Miami/Jackson Health System
Present

U.S. Department of Health and Human Services
2017–2019
Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2014–2017
Internal Medicine
Baylor College of Medicine
2010–2013
University of Crete School of Medicine
2003–2007

Research

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Journal of Clinical Oncology · 2021 · 172 citations
Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Review · Clinical Microbiology and Infection · 2009 · First of 4 authors · 92 citations
Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis
Journal of the American Academy of Dermatology · 2020 · 47 citations

Izidore Lossos
7 papers
Dimitrios Kontoyiannis
5 papers
AD
Alexey Danilov
3 papers
AK
Anita Kumar
3 papers
BK
Brad Kahl
3 papers
Brian Hill
3 papers
Christina Annunziata
3 papers
Eric Mou
3 papers
Jia Ruan
3 papers
Jonathon Cohen
3 papers
Juan Alderuccio
3 papers
MA
Maryam Alasfour
3 papers · 3 as a fellow

Clinical trials

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2038
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Site PI · Recruiting · Phase 2
City of Hope Medical Center
2026–2029
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2028